Trials / Recruiting
RecruitingNCT07144020
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
Donor Derived CD117 CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Clinical Study on the Safety and Effectiveness of Donor Derived CD117 CAR-T Cell in the treatment of Relapsed/Refractory Acute Myeloid Leukemia
Detailed description
This is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety and efficacy of CD117 CAR-T Cell in patients with relapsed or refractory acute myeloid leukemia. It is planned to enroll 15-50 participants in this trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD117 CAR T-cells | Each subject receive CD117 CAR T-cells by intravenous infusion |
Timeline
- Start date
- 2025-09-05
- Primary completion
- 2028-09-05
- Completion
- 2028-09-05
- First posted
- 2025-08-27
- Last updated
- 2025-08-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07144020. Inclusion in this directory is not an endorsement.